



Japan Drug Forecasts to 2024

Conduct external benchmarking & market analysis with the first consensus forecasts for Japan

Our industry-leading consensus forecasts, combined with historical sales and sales by indication for the Japanese market will help you make business critical decisions faster.

Evaluate Japan Drug Forecasts cover over 1,000 marketed and R&D products which make up over 80% of the total Japanese market value in 2016.

Product Valuation

Create product and company portfolio valuations for Japan market with standardised consensus forecasts to 2024

Competitive Analysis

Benchmark product performance and map uptake trends and key drivers for Japan market

Market Sizing

Model the future dynamics of the Japanese market to 2024 and compare worldwide, USA and EU consensus forecasts


Sales by Indication

Model product sales at indication level and identify the key growth drivers

Horizon Scanning

Map pipeline assets likely to launch by 2024 and measure impact to understand future asset value

1,000+ Products covered – >80% of total Japan market in 2016



Sales by indication

Available for the top 25+ companies, including Takeda, Astellas Pharma, Daiichi Sankyo, Roche and more.





Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalized, expert support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

EvaluatePharma offers a global view of the pharmaceutical market's past, present and future performance with consensus forecasts to 2024, company financials, pipelines and deals.

EvaluatePharma^{Vision} provides the first single view of the risk and return of the R&D landscape with consensus forecasts, R&D costs at drug and trial level, success rates, predictive timelines and trial outcomes.

EvaluateMedTech tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2024, company financials and more.

Evaluate Custom Solutions improves your strategic decision-making with customized solutions and deep insights that draw on our industry expertise and trusted commercial intelligence.

Evaluate Vantage provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate's commercial intelligence.

www.evaluate.com | [@EvaluatePharma](https://twitter.com/EvaluatePharma) [@EvaluateVantage](https://twitter.com/EvaluateVantage)

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom

T +44 (0)20 7377 0800

Evaluate Americas

EvaluatePharma USA Inc.
60 State Street, Suite 1910
Boston, MA 02109
USA

T +1 617 573 9450

Evaluate Asia Pacific

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052, Japan

T +81 (0)80 1164 4754